Pilot Projects Program
The goal of the Pilot Projects Program is to stimulate growth of expertise and engagement in clinical and translational research. This program will fund a variety of awards and provide a mechanism for clinician/non-clinician teams to develop promising new translational research projects focused on cancer.
DaCCoTA Pathfinder
By enrolling in the DaCCoTA Pathfinder, you can search and view the research profiles of other scientists and clinicians in the DaCCoTA Network to find collaborators.
Enroll in the DaCCoTA Pathfinder network to find collaborators
Pilot Awards Offered Through the DaCCoTA
RFA for COVID-19-Related Applications
This award is intended for projects that address the intersection between cancer and/or cancer-related care and the COVID pandemic environment. Applications should focus on T2- T4 translational research, although T1 studies will be considered if there is a clear plan to progress to T2-T4.
Letter of Intent Deadline: Letters of intent will be accepted on a rolling basis but no later than May 1, 2020.
Application Deadline: Full applications will be invited from selected applicants with submissions accepted
on a rolling basis but no later than May 22, 2020.
Anticipated Award Period: July 2020 - June 2021
RFA for Covid-19-Related Applications
Previous RFAs (check back soon for new RFAs for the funding mechanisms below)
Community Engagement
The Community Engagement Pilot Grant Awards are intended for those projects addressing priority areas as determined by key stakeholder groups including the American Cancer Society, Community Health Association of the Dakotas, ND Department of Health, and the Great Plains Tribal Chairmen’s Health Board.
RFA for proposals addressing cancer disparities in either (1) colorectal cancer screening, stage and diagnosis, treatment, and mortality (2) tobacco-related cancers (lung, CRC, etc.), or (3) breast cancer screening, stage at diagnosis, and mortality
Letter of Intent Deadline: January 24, 2020
Application Deadline: March 16, 2020
Anticipated Award Period: September 2020 - August 2021
Feasibility
The Feasibility Pilot Awards are designed to allow a clinician/non-clinician team to form around a novel cancer-related hypothesis. Applications can consider the multilevel manifestations of cancer (e.g. neurological, psychiatric), demographic risks and social impact. Applications should focus on T2-T4 translational research, although T1 studies will be considered if there is a clear plan to progress to T2-T4. The primary goal is to allow a team to form and connect with the CTR Biostatistics, Epidemiology, and Research Design Core; Clinical Research Resources and Facilities Core; Community Engagement and Outreach Core; and Pilot Projects Program to generate competitive proposals for the CTR Ready-to-Go Pilot Award mechanism.
RFA for Feasibility Pilot Awards
Letter of Intent Deadline: January 24, 2020
Application Deadline: March 16, 2020
Anticipated Award Period: September 2020 - August 2021
Ready-to-Go
The Ready-to-Go Pilot Awards are intended for those projects with existing significant preliminary data in support of a novel clinical/translational cancer-related hypothesis. Applications can consider the multilevel manifestations of cancer (e.g. neurological, psychiatric), demographic risks and social impact. Applications will focus on T2-T4 translational research, although T1 studies will be considered if there is a clear plan to progress to T2-T4. Successful completion of these proposals should lead to a collaborative extramural grant submission and peer-reviewed manuscript submission.
RFA for Ready-to-Go Pilot Awards
Letter of Intent Deadline: January 24, 2020
Application Deadline: March 16, 2020
Anticipated Award Period: September 2020 - August 2021
Core Faculty
- Dr. Combs is Chester Fritz Distinguished Professor and Chair of the Department of Biomedical Sciences at the University of North Dakota School of Medicine and Health Sciences. He studies signaling mechanisms in both excitable and non-excitable cells, and his lab has been instrumental in studying the MAP kinase pathway and its role in cell proliferation and development. Recently, he has branched out into studying the role of glia cells in neuroblastoma formation. He also has experience working with preclinical models and has worked with several clinicians to translate many of his findings. He recently began working with VA investigators to identify the role of the microbiome in various diseases. He has published more than 70 publications in high-profile journals and is a principal investigator on three R01 grants. He is a standing member of both NIH and VA study sections and serves on the editorial board of numerous journals.
- Dr. Venkatachalem is an Assistant Professor who directs a cellular physiology and biochemistry laboratory in the Department of Pharmaceutical Sciences of the School of Pharmacy at North Dakota State University (NDSU). The primary focus of Dr. Venkatachalem’s research is sex/gender differences in lung disease. He also studies cancer nanomedicine therapy by examining sex steroids and the signaling of their specific receptors in the breast cancer. Dr. Venkatachalem received his PhD in biochemistry from the University of Madras and completed his initial postdoctoral training in physiology at the University of Western Ontario, Canada. He received further training and worked in pre-clinical research settings at the Mayo Clinic in Rochester, MN for 10 years. Currently, he is establishing pre-clinical and translational research collaborations between NDSU and clinicians at Veterans Affairs and the Sanford Hospitals in Fargo. Dr. Venkatachalem’s laboratory is supported by multiple research grants including an NIH R01, NIH Sex/Gender Research supplement, and ND EPSCoR as well as funding from the Flight Attendant Medical Research Institute.
Contact DaCCoTA if you have any questions about the Pilot Projects Program.